Clinical Publication
RSSArticles
-
Teplizumab-mzwv Injection (Tzield)
Teplizumab can be prescribed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients age 8 years and older with stage 2 type 1 diabetes.
-
It’s Not All About the Cough
Be careful about relying on clinical queries that focus on the presence of cough for two or more weeks, which could lead to delays in the diagnosis of nearly half of pulmonary tuberculosis cases.
-
Is Routine Stress Testing After Coronary Revascularization Necessary?
A multicentered study of routine stress testing at one year post-percutaneous coronary revascularization compared to usual care in patients with at least one high-risk coronary anatomic or clinical feature failed to show improved clinical outcomes at two years follow-up.
-
Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding for those taking apixaban during venous thromboembolism treatment compared to warfarin in patients with end-stage kidney disease.
-
Patients with Chronic Pain and Opioid Misuse: What Treatment Works?
Among primary care patients diagnosed with comorbid chronic pain and opioid misuse, researchers found a specially designed, mindfulness-based group therapy showed superiority to generic supportive group therapy in reducing opioid use and controlling symptoms of chronic pain.
-
New Therapy for Resistant Hypertension
Aprocitentan demonstrated efficacy for additional therapy beyond standard multidrug treatment in resistant hypertension.
-
Is Screening for Atrial Fibrillation Cost Effective?
Self-screening for atrial fibrillation in elderly individuals could lead to lower stroke rates, prevent bleeding-related hospitalizations, and save money.
-
Is It Better to Up-Titrate Medications Faster in Acute Heart Failure Patients?
Early intensive up-titration of guideline-recommended therapy in patients admitted for heart failure reduced 180-day readmission and all-cause mortality at the cost of more adverse events (but not serious or fatal ones).
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.
-
Mitral Transcatheter Edge-to-Edge Repair Gains Traction in Cardiogenic Shock Patients
The authors of this large registry study examined transcatheter edge-to-edge repair in patients with cardiogenic shock and severe mitral regurgitation (MR). Successful repair was achievable in most patients and was associated with lower mortality rates and heart failure hospitalization at one year.